How Does Cannabis Rescheduling Affect Medical Use?
Cannabis moving to Schedule III would end 280E taxes and ease research. State medical programs, insurance, VA rules, and possession penalties stay the same.
Cannabis rescheduling is a federal rule change that would move marijuana out of Schedule I of the Controlled Substances Act and into a lower schedule. In May 2024 the DEA proposed placing cannabis in Schedule III, the same category as ketamine and codeine-based products. That proposal is not final, so cannabis stays Schedule I under federal law today.
The Controlled Substances Act of 1970 sorts drugs into five schedules. The sorting turns on two questions: does the drug have an accepted medical use, and how likely is it to be abused.
Rescheduling means the drug stays controlled. It moves to a different list with different rules. It does not remove the drug from federal law.
A move to Schedule III would touch three areas. Several others would stay the same.
Cannabis Rescheduling Impact on Legality: A Comprehensive Guide
What would change
What would not change
No. Legalization would remove cannabis from the Controlled Substances Act or write federal rules for sale and possession. Rescheduling keeps the drug controlled and keeps federal criminal law in place for unlicensed activity.
Think of it as a change of category, not a change of status. A Schedule III drug still requires a prescription to possess under federal law, and cannabis has no FDA-approved prescription framework.
In October 2022 the Biden administration asked federal health agencies to review how cannabis is scheduled. The Department of Health and Human Services finished that review in 2023 and recommended Schedule III to the DEA. The DEA then published its proposed rule in the Federal Register in May 2024.
The 2024 proposal cleared step two. Hearings and agency review are still underway, and no final order has been issued.
For shoppers in legal states, most of the buying experience would look the same: same dispensaries, same labels, same age rules. The larger shifts would land on the business side.
No. State bans stay in place. A state that prohibits cannabis can keep enforcing its own law after a federal schedule change.
Possibly, over years. Tax savings for licensed operators could show up in retail prices, but state taxes, license caps, and supply costs drive most of the sticker price.
No. Air travel crosses federal jurisdiction, and federal law applies at airports and in the air. Schedule III drugs also require a valid prescription to possess, which cannabis does not have.
It could ease research and let doctors study cannabis with less paperwork. It would not create a federal medical program, and state medical cards would keep working the way they work now.
The DEA's final order is the deciding step. Lawsuits from either side could follow, and Congress could pass separate bills on banking or federal legalization. Until a final order lands in the Federal Register, nothing about federal cannabis law has changed.
For now, treat rescheduling as a pending rule, not a done deal. State-legal shops, delivery services, and online sellers operate under state licenses, and that part of the market keeps running on state rules.